73monte said...
Just wanted to mention, while @beave has left you a couple of excellent posts which I'm sure will help you, clinically, Entyvio doesn't seem to be getting anywhere near the success rates of Remicade. We have many new meds, with many more to come, but as of right now, Remicade is still the state of the art treatment that we have.
That's correct about
Remicade having the best odds of success. Even though it has been out the longest, studies show it's still the most likely drug to help.
Entyvio doesn't have as good of odds, especially for Crohn's disease. But for UC, Entyvio has pretty good results - not quite the results of Remicade, but better than several other drugs. And Entyvio also has about
the lowest risks of side effects of any of the biologics.
So, as always, deciding what to use is a combination of assessing the patient's overall health and risk tolerance and balancing that with the chances of working for the different drugs now available as options.